FACT SHEET

MANULIFE DANA EKUITAS INDONESIA INDIA - IDR

FEB 2025

To generate capital appreciation by investing in medium to long term in Indonesian equities and/or companies listed on the Indian stock exchange that derive majority of their revenue from India.

Fund Information

1 Jul 11 Inception Date Inception Price IDR 1,000.00 Rp 178.06 bn Fund Size 120,889,123.55 Number of unit IDR 1,472,94 Net Asset Value/Unit 4) Fund Currency IDR Type of fund Equity Valuation Daily

Custodian Bank Standard Chartered Ban

Annual Management Fee 2.50% Bloomberg Code MITDELLI

Fund Manager PT Manulife Aset Manajemen Indonesia

Risk Classification



- 1) Annualized (1 year = 365 days) and using compound method (for products that have been more than one year old since inception).
- 2) The henchmark is 85% JCI + 15% NIFTY Index in IDR terms
- 3) Based on GICS (Global Industrials Classification Standard).
- 4) The Net Asset Value / Unit has calculated the costs, including fees related to transaction and transaction settlement as well as administration and recording

Performance Since Inception



Monthly Performance Last 3 Years



Fund Performance

Performance in IDR per (28/02/25)											
	1 mo	3 mo	6 mo	YTD	1 yr	3 yr ¹⁾	5 yr ¹⁾	Since Inception 1)			
MDEII (in IDR)	-12.68%	-15.59%	-19.37%	-14.81%	-18.16%	-15.16%	1.77%	2.87%			
BM 2)	-10.84%	-11.16%	-17.03%	-10.68%	-12.00%	-1.09%	4.62%	4.76%			

Yearly Performance												
	2024	2023	2022	2021	2020	2019	2018	2017				
MDEII (in IDR)	-6.62%	-13.02%	-11.94%	43.72%	6.03%	-1.07%	-7.24%	16.99%				
BM 2)	-0.41%	8.05%	4.14%	12.11%	-2.26%	2.53%	-1.87%	22.61%				

Top Holdings* & Sector Allocation31

Stock - Aneka Tambang Tbk

Stock - Astra International Tbk PT

Stock - Axis Bank Ltd

Stock - Bank Central Asia Tbk PT

Stock - Bank Mandiri Persero Tbk PT

Stock - Bank Negara Indonesia Persero Tbk PT Stock - Bank Pan Indonesia Tbk PT

Stock - Bank Rakyat Indonesia Persero Tbk PT

Stock - Bank Syariah Indonesia Tbk PT

Stock - Bundamedik Tbk PT

Stock - Chandra Asri Pacific Tbk PT

Stock - GoTo Goiek Tokopedia Tbk PT

Stock - HCL Technologies Ltd

Stock - Hillcon Tbk PT

Stock - ICICI Bank Ltd

Stock - Impack Pratama Industri Tbk PT

Stock - Indofood CBP Sukses Makmur Tbk PT

Stock - Indofood Sukses Makmur Tbk PT

Stock - Indosat Tbk PT

Stock - Infosys Ltd

Stock - Mayora Indah Tbk PT

Stock - Panin Financial Tbk PT


Stock - Reliance Industries Ltd Stock - Sun Pharmaceutical Industries Ltd

Stock - Telkom Indonesia Persero Tbk PT

Stock - Triputra Agro Persada PT

Stock - UltraTech Cement Ltd

Stock - United Tractors Tbk PT



Equity market posted negative performance in February due to uncertainty on US tariff policy and concern on weak domestic growth. President Trump affirms that 25% against imports from Canada and Mexico will proceed in early March, along with 10% additional tariff against China. President Trump also indicate that further tariffs would follow in April, to impose reciprocal tariffs against countries that imposed tariffs on US. Domestically, concerns on weak domestic growth and uncertainty on government policy transition weighed on market sentiment. There was deflation -0.09% YoY in February, seen by the market as indication of weak domestic consumption. Meanwhile the government announced further budget efficiency to reach IDR750 trillion to be reallocated to priorities program such as Free Nutritious Lunch program, and forming Danantara. Bank Indonesia maintained BI Rate at 5.75% amild weak Rupiah that depreciated -1.7% against USD to 16,580. However BI maintains outlook of further rate cut to support domestic growth. India equities also fell in the month, pressured by foreign selling amid concern on weaker domestic growth outlook. Portfolio allocations in utilities contributed positive attributions, meanwhile allocations in IT contributed negative attributions to performance.

Disclaimer: This report is prepared by PT Asuransi Jiwa Manulife Indonesia only for information purposes and not to be used as a sales offering or proposal. Although this report has been prepared meticulously, PT Asuransi Jiwa Manulife Indonesia does not guarantee its accuracy, sufficiency or completeness, and is not responsible for any consequences arising from any actions which are based on the information stated herein. Investments in capital market instruments are subject to various risks which include, but not limited to, market risk, credit risk, interest rate risk, exchange rate risk (particularly in Fund which has allocation in offshore investment instruments in different currencies than the Fund's currency), liquidity risk and other risks which could result in performance volatility. Therefore, the performance of this Fund is not guaranteed, the unit price of each Fund may go up or down and past performance does not necessarily indicative of future performance.









